

## Quetiapine Extended-Release Tablets

<b>Type of Posting</b>	Revision Bulletin
<b>Posting Date</b>	27-Aug-2021
<b>Official Date</b>	1-Sep-2021
<b>Expert Committee</b>	Small Molecules 4

In accordance with the Rules and Procedures of the Council of Experts, the Small Molecules 4 Expert Committee has revised the Quetiapine Extended-Release Tablets monograph. The purpose of the revision is to add *Dissolution Test 10* to accommodate FDA-approved drug products with different dissolution conditions and/or tolerances than the existing dissolution test(s). The revision also necessitates a change in the table numbering in the test(s) for *Organic Impurities*.

The Quetiapine Extended-Release Tablets Revision Bulletin supersedes the currently official monograph.

Should you have any questions, please contact Claire Chisolm, Senior Scientist II (301-230-3215 or [cnc@usp.org](mailto:cnc@usp.org)).